डासाटिनिब और वोरिकोनाज़ोल का इंटरैक्शन

Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of voriconazole.

Avoid concomitant use of strong CYP3A4 inhibitors.

If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction [see Dosage and Administration ( 2.3 )] .

DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Dose reduction may be necessary.

Effect of Other Drugs on Dasatinib Strong CYP3A4 Inhibitors The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations [see Clinical Pharmacology ( 12.3 )] .